Regulatory Articles
Regulatory Beat: Pharmaceutical Pricing and Healthcare Access Lead Policy Agenda
Rising healthcare costs and the pressure to expand medical coverage focus public attention on medicine outlays.
For full article Click Here
Cohen's Corner: Don't sell out the value of pharmacy
When did retail pharmacy, and, more specifically, the art and professionalism of dispensing a prescription become a commodity? I'm sure every retail pharmacist has a different answer depending on how new he or she is to the profession; I know I do. For me, it was back in 1969, when I was just fresh out of school, thinking that pharmacy was the greatest profession in the world. The store I interned in had its fair share of indigent patients who got their prescriptions filled on what was then a small federal government program known as Medicaid.
For full article Click Here
Independent Movement of the Regulatory and Catalytic Domains of Myosin Heads
flexibility of the myosin head was measured using phosphorescence anisotropy of selectively labeled parts of the molecule. Phosphorescence anisotropy was measured in soluble S1 and myosin, with and without F-actin, as well as in synthetic myosin filaments. The anisotropy of the former were too low to observe differences in the domain mobilities, including when bound to actin. However, this was not the case in the myosin filament.
For full article Click Here
PhRMA Perspectives on Drug Substance Regulatory Filing Issues
Tom Cupps,Betsy Fritschel,Wendy Mavroudakis,Michael Mitchell, Dave Ridge, and Jean Wyvratt The PhRMA API Technical Group examines topics concerning active pharmaceutical ingredient development and manufacture and makes recommendations for regulatory guidance.
For full article Click here
Upgrading a Pharmaceutical Laboratory to Part 11 Compliance
FDA's regulation 21 CFR Part 11 on Electronic Records and Electronic Signatures provides industry with the requirements that allow electronic records and signatures in computerized systems in place of paper records and handwritten signatures.1
For full article Click Here
European Regulatory Agencies Resource Locator
Change is in the air for European regulations. Formal legislative proposals might not appear until 2002, but the shape of the changes is beginning to become clear
For full article Click Here
Dissolution testing: An overview and a summary of recent trends and regulatory a
Dissolution testing is critical to measuring the performance of pharmaceutical products in tablet and capsule form. It is a relatively new analytical technique, and equipment modifications and improvements span the decade. This article gives an overview of the apparatuses and procedures used in dissolution testing. It also summarizes the activities of the major organizations and groups that influence dissolution testing standards.
For full-text article Click Here
Part 11 Is Not Going Away: The New Electronic Records Draft Guidance
The rules for electronic records and signatures still remain in effect. The change means that companies must now justify their decisions on whether or not to implement specific electronic controls with documented risk assessments and considerations of the record requirements detailed in the corresponding predicate rule.
View Full Article
Anticipating New Regulatory Hurdles
The potential of the biotechnology industry to provide blockbuster products is clearly demonstrated by examples like Enbrel (for the treatment of rheumatoid arthritis in adults and of active polyarticular-course juvenile chronic arthritis), Remicade (for the treatment of rheumatoid arthritis and Crohn's disease), and MabThera (for treatment of stage III-IV follicular lymphoma and CD20 positive diffuse large B-cell non-Hodgkin's lymphoma).
View Full Article
Manufacture of Sterile Active Pharmaceutical Ingredients, guidance, 1999
Active Pharmaceuticals Ingredients Committee of CEFIC.
